All In MedTech

FDA Clearance Tracker · K201269

Accula Strep A Test

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Nov 9, 2020 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Nov 9, 2020

Substantially Equivalent

Time to decision

181 days

Received May 12, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Dual Track

Device class

Class II

The decision

FDA number
K201269
Device name
Accula Strep A Test
Applicant location
San Diego, CA
Received
May 12, 2020
Decided
Nov 9, 2020
Decision
Substantially Equivalent
Submission type
Dual Track

Device type

Device class
Class II
Regulation
21 CFR 866.2680

Every decision under product code PGX

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PGX. The earliest in FDA's data is DEN140005, decided Apr 16, 2014.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Mesa Biotech, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.